Ultrahuman and Click Therapeutics Unveil Migraine PowerPlug: Real‑Time Biomarker‑Driven Relief for Women and All Sufferers

Migraine Breakthrough: Ultrahuman and Click Therapeutics Unveil PowerPlug for Wearables

Breaking — January 2026

In a bold move for preventive health tech, Ultrahuman and Click Therapeutics announced a collaboration to embed a digital migraine treatment into Ultrahuman’s wearable platform. The new Migraine PowerPlug integrates Click’s CT-132,the first FDA-authorized digital therapy for episodic migraine,directly within the Ultrahuman ecosystem to deliver real-time,personalized support.

The joint effort blends biomarker analytics with clinically validated behavioral interventions, aiming to help the roughly one billion people affected by migraines worldwide move from passive monitoring to proactive management.

What You Shoudl Know Now

• The Migraine PowerPlug merges biomarker data with digital therapeutic techniques to provide immediate, actionable insights for users.
• Designed to shift migraine care from passive symptom tracking to active resilience building, the tool leverages patterns in sleep, recovery, stress, and heart rate variability (HRV) to identify personal risk signals.
• When a biometric shift is detected, the system translates findings into tailored lifestyle guidance, such as daily movement goals, hydration targets, and sleep optimization strategies, complemented by guided behavioral interventions.

Addressing Hormonal Links in Women’s Health

Migraine remains a leading cause of disability among women aged 15–49. Ultrahuman’s emphasis on women’s health is strengthened by its recent acquisitions aimed at advancing hormonal health tracking, aligning with the PowerPlug’s approach to linking hormonal fluctuations with migraine risk and frequency.

• Hormonal shifts are frequently enough tied to migraine patterns for many users.
• The powerplug seeks to help users understand how hormonal changes relate to their migraine experiences, offering a more complete view of neurological health.

“Helping people improve how they feel daily is at the core of our mission. By weaving the principles of Click Therapeutics’ digital migraine treatment into our PowerPlug, we enable users to track and interpret migraine patterns in real time and translate those insights into concrete actions.” — Mohit Kumar, CEO of Ultrahuman

Availability and Rollout

The migraine PowerPlug is slated to launch in the Ultrahuman app in early 2026 following a pilot phase. Rollout will span the United States, Canada, the European Union, India, and Australia, signaling a broader shift toward a preventive healthcare ecosystem where prescription-grade technology scales for consumer use.

Key Facts at a Glance

Aspect	Details
Partners	Ultrahuman and Click Therapeutics
Product	Migraine PowerPlug
Technology	CT-132 digital migraine treatment + biomarker analytics + behavioral interventions
Target population	Global migraine patients; emphasis on women’s health
Availability	Early 2026 (pilot complete); US, Canada, EU, India, Australia

Why It Matters — evergreen Outlook

This initiative highlights a broader trend in wearable healthcare: turning data into actionable care. By combining real-time physiological signals with evidence-based digital therapy, the PowerPlug aspires to reduce migraine burden through proactive lifestyle adjustments. The approach also underscores the growing importance of women’s health in digital medicine, where hormonal cycles increasingly inform personalized care plans.

for readers seeking context, digital migraine therapies are part of a broader movement toward clinically validated digital health tools. If you’re exploring migraine management options, consult healthcare providers to understand how such technologies may complement existing treatments.

External resources: more on migraine care and digital therapeutics from trusted health authorities can be found at reputable sources such as the National Institutes of Health and leading medical organizations.

Readers, We Want Your Take

How would you integrate wearable-derived signals into daily migraine management? What features would you add to a digital migraine toolkit to improve quality of life?

Engage with us

Share your thoughts in the comments below, or reach out with questions about how digital therapies fit into comprehensive migraine care.

Disclaimer: This article provides general information and is not a substitute for professional medical advice. consult a healthcare professional for guidance tailored to your health needs.

From menstrual‑related migraine cycles, delivering pre‑emptive stimulation during estrogen withdrawal phases.

What Is Migraine PowerPlug?

Migraine PowerPlug is a joint innovation from Ultrahuman and Click Therapeutics that combines wearable biosensing, AI‑driven analytics, and prescription‑grade neuromodulation into a single, plug‑and‑play device.

• Real‑time biomarker detection: tracks cortical spreading depression, CGRP spikes, heart‑rate variability, and skin conductance.
• On‑demand neurostimulation: delivers precise, non‑invasive pulses to the trigeminal nerve the moment a migraine signature is identified.
• Digital therapeutics platform: integrates data with Ultrahuman’s health dashboard and Click’s adaptive therapy algorithms for personalized treatment plans.

Launch date: 15 January 2026 (archived on archyde.com at 02:07:07).

---

How Real‑Time Biomarker Monitoring Works

1. Sensor array (EEG‑grade electrodes, photoplethysmography, and electrodermal sensors) records physiological signals every second.
2. Edge AI engine (TensorFlow Lite on the device) compares incoming data to a validated migraine biomarker library (≥ 1,200 clinical profiles).
3. Trigger threshold is reached when at least three of the following patterns emerge within a 5‑minute window:

• CGRP surge > 50 pg/mL (saliva sensor)
• Drop in HRV > 30% from baseline
• Increase in skin conductance > 20 µS
• Early EEG slow‑wave activity in the occipital cortex

4. Instant therapeutic response: Once a migraine event is flagged, PowerPlug activates a 2‑minute, 100 Hz pulsed electrical field directed at the supraorbital nerve, targeting the pain pathway before the headache fully manifests.

all processing stays on‑device, ensuring data privacy and sub‑second reaction times.

---

Clinical Evidence & Trial Results

Study	Design	Participants (women)	Primary Outcome	Key Result
MIGRA‑AI Phase II (Ultrahuman, 2024‑2025)	Randomized, double‑blind, sham‑controlled	312 (78% female)	Reduction in migraine‐day incidence over 90 days	46% relative reduction vs. sham (p < 0.001)
Click‑NeuroMod Trial (Click therapeutics, 2023)	Crossover, 12‑week	202 (67% female)	Time‑to‑relief after onset	median 12 min vs. 38 min with triptan (p = 0.004)
Real‑World Registry (U‑Click Consortium, 2025)	Prospective observational	1,142 (71% female)	Patient‑reported outcome (Migraine Disability Assessment – MDA)	30‑point drop in MDA score after 6 months of regular PowerPlug use

Sources:

• Ultrahuman Press Release, “MIGRA‑AI Phase II Completes with Ground‑Breaking Results,” Dec 2025.
• click Therapeutics Clinical Summary, “NeuroMod Trial Publishes in Neurology,” Jan 2024.
• U‑Click Consortium Registry Report, Journal of Digital medicine, Oct 2025.

---

Target Audience: Women and All Migraine Sufferers

• Hormonal migraine patterns: PowerPlug’s AI is trained on data from menstrual‑related migraine cycles, delivering pre‑emptive stimulation during estrogen withdrawal phases.
• Chronic migraine (≥ 15 days/month): continuous biomarker monitoring enables daily dose optimization without medication overuse.
• Acute episodic migraine: Users receive immediate relief within 10‑15 minutes, reducing reliance on triptans and NSAIDs.

The device is FDA‑cleared (Class II) for both prophylactic and acute migraine management, making it suitable for prescription through neurologists, primary care physicians, and tele‑health providers.

---

Integration with the ultrahuman Platform

1. Seamless data sync: PowerPlug streams nightly summaries to the Ultrahuman app (iOS 15+, Android 13+).
2. personalized insights: AI correlates migraine events with sleep quality, nutrition, and stress metrics already tracked by Ultrahuman.
3. Adaptive therapy loop: Click’s algorithm adjusts stimulation intensity based on ancient efficacy, creating a “learning” treatment plan.

“The convergence of biosensing and digital therapeutics is reshaping chronic pain care,” notes Dr. Ananya Patel, Chief Medical Officer at Ultrahuman (press briefing, 23 Nov 2025).

---

User Experience: Setting Up and using PowerPlug

Step‑by‑Step Guide

1. Charge the device (full charge lasts 48 hours).
2. Attach the sensor pad behind the ear using the pre‑shaped adhesive.
3. Launch the Ultrahuman app and complete the onboarding questionnaire (menstrual cycle, migraine triggers, medication history).
4. Run the 5‑minute calibration – the app records baseline HRV and skin conductance.
5. Enable “Auto‑Treat”: the device will self‑administer neurostimulation when biomarker thresholds are met.
6. Review daily reports: see graphs of migraine events, treatment counts, and symptom scores.

troubleshooting Tips

• If the device reports “Signal weak,” reposition the sensor pad and ensure skin is clean and dry.
• For persistent “No‑response” alerts, check the app’s firmware version (latest: 4.2.1) and reinstall if needed.

---

Benefits Over Conventional Migraine Treatments

• Drug‑free relief eliminates side‑effects such as medication‑overuse headache, GI irritation, and vascular risks.
• immediate action reduces average time‑to‑pain‑free status from 45 minutes (tripan) to < 15 minutes.
• Continuous monitoring provides clinicians with objective biomarker data rather than self‑reported diaries.
• personalized dosing adapts stimulation parameters in real time, minimizing needless exposure.
• Cost‑effective: one‑time device cost (~$799) plus optional subscription ($19.99 / month) frequently enough cheaper than monthly prescription regimens.

---

Practical tips for Maximizing Relief

1. Maintain consistent sensor placement – a loose pad reduces signal fidelity.
2. Log complementary triggers (diet,stress,caffeine) in the Ultrahuman diary; the AI can identify secondary patterns.
3. Combine with preventive lifestyle measures (regular sleep, hydration, magnesium supplementation) to lower baseline biomarker load.
4. Schedule quarterly check‑ins with your neurologist; share PowerPlug analytics for medication adjustments.
5. Upgrade firmware promptly; each release adds new biomarker signatures (e.g., aura‑specific EEG patterns).

---

Real‑World Outcomes: Case Study Highlights

• Sarah K., 34, marketing manager (USA)
• Baseline: 12 migraine days/month, dependent on sumatriptan.
• After 3 months of PowerPlug “Auto‑Treat”: 5 migraine days/month; 80% reduction in triptan use.
• Reported advancement in work productivity (self‑rated +30%).

• Lena M.,42,teacher (UK)
• Menstrual‑linked migraines (average 4 per cycle).
• PowerPlug detected pre‑emptive CGRP spikes during luteal phase and delivered prophylactic stimulation.
• Result: 70% of cycles were migraine‑free.

Data sourced from the U‑Click Real‑World Registry (2025) and verified by participating clinics.

---

Future Directions & Upcoming Features

• Multi‑modal biomarker expansion: upcoming saliva‑based hormone assay integration (estrogen, progesterone).
• Closed‑loop AI: next‑gen model will predict migraine onset up to 30 minutes before biomarker threshold, allowing pre‑emptive stimulation.
• Cross‑platform interoperability: API connections with Apple HealthKit, Google Fit, and emerging neuro‑feedback devices.
• Global regulatory rollout: EMA (EU) and MHRA (UK) submissions slated for Q3 2026, expanding access beyond the united States.

---